Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression

Gene Therapy

Volumn 4, Issue 8, 1997, Pages 853-860

  Schowalter, D B ^a   Meuse, L ^a   Wilson, C B ^a,b   Linsley, P S ^a   Kay, Ma ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Canine factor IX; CD28 B7 1 or B7 2; Human alpha 1 antitrypsin inhibitor; Immune evasion; Liver; Recombinant adenovirus

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; FEMALE; GENE EXPRESSION; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; T LYMPHOCYTE; TRANSGENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0030847771     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300466     Document Type: Article

References (29)

1. Barr D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995, 2: 151-154.
2. Smith TA et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-102.
3. Tripathy S, Black H, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550
4. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
5. Yang Y, Wilson J. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996; 273: 1862-1864.
6. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
7. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
8. Kay MA et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA41g enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686-4691.
9. Bluestone JA. New perspectives of CD28-B7 mediated T cell costimulation. Immunity 1995; 2: 555-559.
10. Azuma M et al. B70 antigen is a second ligand for CTLA4 and CD28. Nature 1993; 366: 76-79.
11. Hathcock KS et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. Science 1993; 262: 905-909.
12. Freeman G et al. Murine B7-2, an alternative CTLA4 counter receptor that costimulates T cell proliferation and IL-2 production. J Exp Med 1993; 178: 2185-2192.
13. Freeman G et al. Cloning of B7-2: a CTLA4 counter receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
14. Kearney ER, Walunas TL, Karr RW. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4 T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA4. J Immunol 1995; 155: 1032-1036.
15. Waterhouse P et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 1995; 270: 985-988.
16. Linsley P, Ledbetter JA. The role of the CD28 receptor during T cell response to antigen. Ann Rev Immunol 1993; 11: 191-212.
17. Wallace PM, Rodgers JN, Leytze GM. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J Immunol 1995; 154: 5885-5895.
18. Vrancken-Peeters MJTFD, Lieber A, Perkins J, Kay MA. Method for multiple portal vein infusions in mice, quantitation of adenovirus-mediated hepatic gene transfer. BioTechniques 1996; 20: 278-285.
19. Schowalter DB et al. Heterologous expression of adenovirus E3-gp19K in an El deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Therapy 1997; 4: 351-360.
20. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
21. Linsley PS et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T-cell activation molecule. Science 1992; 257: 792-795.
22. Yang Y et al. Immune response to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
23. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig Science 1994; 265: 1225-1227.
24. Lieber A, Vrancken-Peeters MJTFD, Kay MA. Adenovirus-mediated transfer of the amphotrophic retrovirus receptor cDNA increases retroviral transduction in cultured cells. Hum Gene Ther 1995; 6: 5-11.
25. Kay MA, Graham F, Leland F, Woo SL. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 1995; 21: 815-819.
26. Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs Proc Natl Acad Sci USA 1994; 91: 2353-2357.
27. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
28. Hitt M, Bett AJ, Prevec L, Graham FL Construction and propagation of human adenovirus vectors. In: Celis JE (ed). Cell Biology: A Laboratory Handbook. Academic Press: San Diego, 1994.
29. Graham F, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. Bio/Technology 1992; 20: 363-390.